{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:17:59Z","timestamp":1770913079683,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>N\u00e9oVie primary objective was to describe the care pathway of patients with HCV infection treated in addiction centres in France, by evaluating the rate of treatments initiated among these patients and to identify obstacles to treatment initiation. Multicentric, prospective, non\u2010interventional study conducted in France from May 2020 to July 2022. Inclusion criteria were age &gt;\u200918\u2009years, positive HCV RNA, follow up in a participating addiction centre. Direct\u2010acting antiviral (DAA) treatment was initiated at the discretion of the investigators. Patients initiating glecaprevir\/pibrentasvir (G\/P) treatment were followed for up to 11\u2009months after treatment initiation. Data were collected through specific questionnaires. 32 centres participated in the study and 18 were active. Among the 93 patients included, 89 (95.7%) were treated with a DAA (77 (82.8%) with G\/P). After G\/P treatment initiation, all but 2 (which were reinfections) achieved SVR 12 and maintained virological response 6\u2009months later. No AEs with a frequency &gt;\u20093% were reported. Significant improvements were observed between inclusion and 11\u2009months after in terms of quality of life (mean improvement of 6.78\u2009\u00b1\u200921.53 pts (VAS)) and anxiety and depression (10\/37; 27.0% of the patients). These results suggest that once efforts are made in the centre to apply the simplified pathway, it is possible to treat and cure patients with DAA. In order to achieve HCV elimination goal, efforts to promote treatment should continue focusing on training and motivating addiction centres.<\/jats:p>","DOI":"10.1111\/jvh.70121","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:19:48Z","timestamp":1766747988000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing Hepatitis C in Addiction Care Centers: Results of the French Real\u2010Life\n                    <scp>N\u00e9oVie<\/scp>\n                    Study"],"prefix":"10.1111","volume":"33","author":[{"given":"Colette","family":"Gerbaud","sequence":"first","affiliation":[{"name":"CSAPA Malaussena  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyne","family":"Debette\u2010Gratien","sequence":"additional","affiliation":[{"name":"CHU Limoges  Limoges France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Guillouche","sequence":"additional","affiliation":[{"name":"Clinique Jules Verne  Nantes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Fran\u00e7ois","sequence":"additional","affiliation":[{"name":"AbbVie  Rungis France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Dillenschneider","sequence":"additional","affiliation":[{"name":"AbbVie  Rungis France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Reiller","sequence":"additional","affiliation":[{"name":"CSAPA CEID Addiction  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1631-500X","authenticated-orcid":false,"given":"Jean\u2010Pierre","family":"Bronowicki","sequence":"additional","affiliation":[{"name":"CHU Nancy  Vand\u0153uvre\u2010l\u00e8s\u2010Nancy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4057-1649","authenticated-orcid":false,"given":"Jean\u2010Baptiste","family":"Trabut","sequence":"additional","affiliation":[{"name":"CHU Henri Mondor  Cr\u00e9teil France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization \u201cGlobal Hepatitis Report 2024: Action for Access in Low\u2010 and Middle\u2010Income Countries \u201d(2024) accessed May 24 2024 https:\/\/www.who.int\/publications\u2010detail\u2010redirect\/9789240091672."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036913"},{"key":"e_1_2_11_4_1","unstructured":"World Health Organization \u201cCombating Hepatitis B and C to Reach Elimination by 2030 \u201daccessed August 12 2023 https:\/\/www.who.int\/publications\u2010detail\u2010redirect\/combating\u2010hepatitis\u2010b\u2010and\u2010c\u2010to\u2010reach\u2010elimination\u2010by\u20102030."},{"key":"e_1_2_11_5_1","unstructured":"World Health Organization \u201cHepatitis C: Keys Facts \u201daccessed May 24 2024 https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/hepatitis\u2010c."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30505-2"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1826"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00057-8"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200303000-00012"},{"issue":"2","key":"e_1_2_11_10_1","first-page":"144","article-title":"Elimination du Virus de l'h\u00e9patite C (VHC) en France\u2026 Encore un Petit Effort!","volume":"31","author":"Bronowicki J. P.","year":"2024","journal-title":"Hepato\u2010Gastro et Cancerologie Digestive"},{"key":"e_1_2_11_11_1","unstructured":"Sant\u00e9 Publique France \u201cH\u00e9patite C \u201daccessed May 24 2024 https:\/\/www.santepubliquefrance.fr\/maladies\u2010et\u2010traumatismes\/hepatites\u2010virales\/hepatite\u2010c."},{"key":"e_1_2_11_12_1","volume-title":"Caract\u00e9ristiques des personnes prises en charge dans les CSAPA en 2020","author":"Bouthier L.","year":"2023"},{"key":"e_1_2_11_13_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u201cPr\u00e9vention des addictions et r\u00e9duction des risques et des dommages par les centres de soins d'accompagnement et de pr\u00e9vention en addictologie (CSAPA) \u201daccessed February 08 2023 https:\/\/www.has\u2010sante.fr\/jcms\/p_3147889\/fr\/prevention\u2010des\u2010addictions\u2010et\u2010reduction\u2010des\u2010risques\u2010et\u2010des\u2010dommages\u2010par\u2010les\u2010centres\u2010de\u2010soins\u2010d\u2010accompagnement\u2010et\u2010de\u2010prevention\u2010en\u2010addictologie\u2010csapa."},{"key":"e_1_2_11_14_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u201cH\u00e9patite C: Prise en charge simplifi\u00e9e chez l'adulte \u201daccessed December 09 2023 https:\/\/www.has\u2010sante.fr\/jcms\/c_2911891\/fr\/hepatite\u2010c\u2010prise\u2010en\u2010charge\u2010simplifiee\u2010chez\u2010l\u2010adulte."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13798"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.70121","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:27:40Z","timestamp":1770910060000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/jvh.70121"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70121","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"2025-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70121"}}